

(12) **United States Patent**
Luttrull et al.

(10) **Patent No.:** **US 9,427,602 B2**
(45) **Date of Patent:** **Aug. 30, 2016**

(54) **PULSATING ELECTROMAGNETIC AND ULTRASOUND THERAPY FOR STIMULATING TARGETED HEAT SHOCK PROTEINS AND FACILITATING PROTEIN REPAIR**

(71) Applicant: **Ojai Retinal Technology, LLC**, Ojai, CA (US)

(72) Inventors: **Jeffrey K. Luttrull**, Ojai, CA (US);
David B. Chang, Tustin, CA (US);
Benjamin W. L. Margolis, Oakland, CA (US)

(73) Assignee: **Ojai Retinal Technology, LLC**, Ojai, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/922,885**

(22) Filed: **Oct. 26, 2015**

(65) **Prior Publication Data**
US 2016/0082294 A1 Mar. 24, 2016

Related U.S. Application Data
(63) Continuation-in-part of application No. 14/607,959, filed on Jan. 28, 2015, now Pat. No. 9,168,174, which is a continuation-in-part of application No. 13/798,523, filed on Mar. 13, 2013, which is a
(Continued)

(51) **Int. Cl.**
A61F 2/00 (2006.01)
A61N 7/02 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61N 7/022** (2013.01); **A61F 9/00821** (2013.01); **A61N 5/0603** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC A61N 5/062; A61N 2005/0652
USPC 607/88, 89; 600/431, 439
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

3,408,593 A 10/1968 Hurwitz, Jr.
4,048,011 A 9/1977 Kovin et al.

(Continued)

FOREIGN PATENT DOCUMENTS

WO 2006005038 A2 1/2006
WO 2007035855 A2 3/2007
WO 2007 106521 A2 9/2007

OTHER PUBLICATIONS


Yeow, J.T.W. et al.; Micromachined 2-D scanner for 3-D optical coherence tomography; Sensors and Actuators A: Physical, vol. 117, Issue 2, Jan. 14, 2005, pp. 331-340; Elsevier.

(Continued)

Primary Examiner — William Thomson
Assistant Examiner — Jeffrey Lipitz
(74) *Attorney, Agent, or Firm* — Kelly & Kelley, LLP

(57) **ABSTRACT**
A system and method are disclosed for stimulating activation of heat shock proteins and facilitating protein repair in cells and tissues in order to take advantage of the remedial and restorative nature of the increased heat shock protein activation or production and the facilitation of protein repair, while not damaging the cells and tissues. This is accomplished by treating a specified target area with an ultrasound or electromagnetic radiation source which is pulsed and applied or focused to one or more small areas in order to achieve the necessary temperature rise or sufficiently stress the cells and tissue to stimulate heat shock protein production or activation and facilitate protein repair, while allowing the temperature to decay sufficiently quickly so as not to damage or destroy the treated tissue.

16 Claims, 13 Drawing Sheets



Related U.S. Application Data

continuation-in-part of application No. 13/481,124,
filed on May 25, 2012.

- (60) Provisional application No. 62/153,616, filed on Apr. 28, 2015.

(51) Int. Cl.

A61N 5/06 (2006.01)

A61N 5/067 (2006.01)

A61N 7/00 (2006.01)

A61N 5/10 (2006.01)

A61F 9/008 (2006.01)

(52) U.S. Cl.

CPC *A61N5/0625* (2013.01); *A61F 9/008*
(2013.01); *A61F 9/00817* (2013.01); *A61F*
2009/00863 (2013.01); *A61N 5/06* (2013.01);
A61N 5/1017 (2013.01); *A61N 2005/063*
(2013.01); *A61N 2005/0604* (2013.01); *A61N*
2005/067 (2013.01); *A61N 2005/0609*
(2013.01); *A61N 2005/0648* (2013.01); *A61N*
2005/0658 (2013.01); *A61N 2005/0659*
(2013.01); *A61N 2005/0662* (2013.01); *A61N*
2007/0004 (2013.01)

(56)**References Cited****U.S. PATENT DOCUMENTS**

4,176,325 A 11/1979 Kajimura et al.
4,194,114 A 3/1980 Pankratov et al.
4,410,365 A 10/1983 Glukhovskiy et al.
4,695,733 A 9/1987 Pesavento
4,730,335 A 3/1988 Clark et al.
4,791,634 A 12/1988 Miyake
4,865,029 A 9/1989 Pankratov et al.
4,879,722 A 11/1989 Dixon et al.
4,930,504 A 6/1990 Diamantopoulos et al.
4,933,944 A 6/1990 McGraw
4,935,931 A 6/1990 McGraw
4,961,079 A 10/1990 Owens et al.
4,967,416 A 10/1990 Esterowitz et al.
5,037,421 A 8/1991 Boutacoff et al.
5,067,951 A 11/1991 Greve
5,085,492 A 2/1992 Kelsoe et al.
5,088,803 A 2/1992 Buzawa
5,147,354 A 9/1992 Boutacoff et al.
5,348,002 A 9/1994 Caro
5,372,595 A 12/1994 Gaasterland et al.
5,394,199 A 2/1995 Flower
5,430,756 A 7/1995 Hanihara
5,520,680 A 5/1996 Shapshay et al.
5,651,019 A 7/1997 Goldberg et al.
5,982,789 A 11/1999 Marshall et al.
6,055,990 A 5/2000 Thompson
6,066,128 A 5/2000 Bahmanyar et al.
6,143,019 A * 11/2000 Motamedi A61B 18/00
128/898
6,208,769 B1 3/2001 Pankratov

6,222,869 B1 4/2001 Marshall et al.
6,327,291 B1 12/2001 Marshall
6,377,599 B1 4/2002 Marshall
6,540,391 B2 4/2003 Lanzetta et al.
6,640,139 B1 * 10/2003 Ueberle A61B 18/18
607/101
6,681,185 B1 1/2004 Young et al.
6,715,877 B2 4/2004 Molebny
6,733,490 B1 5/2004 Falsini et al.
6,813,942 B1 11/2004 Vozhdaev et al.
6,889,695 B2 5/2005 Pankratov et al.
7,227,196 B2 6/2007 Burgener, II et al.
7,387,785 B1 6/2008 Rudin et al.
7,452,081 B2 11/2008 Wiltberger et al.
7,645,276 B2 1/2010 Pankratov et al.
7,763,828 B2 7/2010 Talwar et al.
7,766,903 B2 8/2010 Blumenkranz et al.
7,766,904 B2 8/2010 McGowan, Sr. et al.
7,771,417 B2 8/2010 Telfair et al.
7,909,816 B2 3/2011 Buzawa
2002/0120255 A1 8/2002 Sotiropoulos et al.
2005/0049582 A1 * 3/2005 DeBenedictis A61B 18/20
606/9
2006/0173512 A1 * 8/2006 Barolet A61N 5/0616
607/86
2008/0015553 A1 1/2008 Zacharias
2010/0049180 A1 * 2/2010 Wells A61N 5/0616
606/12
2010/0092424 A1 4/2010 Sanghvi et al.
2010/0100162 A1 * 4/2010 Peyman A61N 1/403
607/102
2010/0152716 A1 6/2010 Previn et al.
2010/0168724 A1 7/2010 Sramek et al.
2010/0249760 A1 9/2010 Blumenkranz et al.
2010/0290007 A1 11/2010 Van de Velde
2011/0196350 A1 8/2011 Friedman et al.
2012/0165668 A1 * 6/2012 Slayton A61N 7/00
600/439
2014/0148735 A1 * 5/2014 Nau, Jr. A61M 37/0092
601/3

OTHER PUBLICATIONS

Luttrull, JK et al.; Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy Eye (2007), 1-6; Eye advance online publication Jan. 16, 2009.
Luttrull, J K et al.; Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema; Br J Ophthalmol 2005; 89:74-80.
Luttrull, Jeffrey K., MD et al.; Serial Optical Coherence Tomography of Subthreshold Diode Laser Micropulse Photocoagulation for Diabetic Macular Edema; Ophthalmic Surgery, Lasers & Imaging; Sep./Oct. 2006; vol. 37, No. 5; pp. 370-377.
Luttrull, J K et al.; Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema; Eye (2009) Macmillan Publishers Limited 2009.
Small Beam Diameter Scanning Galvo Mirror Systems; Thorlabs; 1999-2013, 4 pgs.
International Search Report for the International application No. PCT/US2015/60893, mailing date Mar. 18, 2016.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6







FIG. 8






FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17

1

PULSATING ELECTROMAGNETIC AND ULTRASOUND THERAPY FOR STIMULATING TARGETED HEAT SHOCK PROTEINS AND FACILITATING PROTEIN REPAIR

RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No. 14/607,959, filed on Jan. 28, 2015; U.S. application Ser. No. 13/798,523, filed on Mar. 13, 2013; and U.S. application Ser. No. 13/481,124, filed on May 25, 2012. This application also claims the benefit of U.S. Provisional Patent Application No. 62/153,616 filed on Apr. 28, 2015.

BACKGROUND OF THE INVENTION

The present invention is generally directed to the activation of heat shock proteins and the facilitation of protein repair. More particularly, the present invention is directed to a system and method for selectively stimulating targeted heat shock protein activation or production and facilitating protein repair utilizing a pulsating electromagnetic or ultrasound energy source.

Heat shock proteins (HSPs) are a family of proteins that are produced by cells in response to exposure to stressful conditions. Production of high levels of heat shock proteins can be triggered by exposure to different kinds of environmental stress conditions, such as infection, inflammation, exercise, exposure of the cell to toxins, starvation, hypoxia, or water deprivation.

It is known that heat shock proteins play a role in responding to a large number of abnormal conditions in body tissues, including viral infection, inflammation, malignant transformations, exposure to oxidizing agents, cytotoxins, and anoxia. Several heat shock proteins function as intra-cellular chaperones for other proteins and members of the HSP family are expressed or activated at low to moderate levels because of their essential role in protein maintenance and simply monitoring the cell's proteins even under non-stressful conditions. These activities are part of a cell's own repair system, called the cellular stress response or the heat-shock response.

Heat shock proteins are typically named according to their molecular weight. For example, Hsp60, Hsp70 and Hsp80 refer to the families of heat shock proteins on the order of 60, 70 and 80 kilodaltons in size, respectively. They act in a number of different ways. For example, Hsp70 has peptide-binding and ATPase domains that stabilize protein structures in unfolded and assembly-competent states. Mitochondrial Hsp60s form ring-shaped structures facilitating the assembly of proteins into native states. Hsp90 plays a suppressor regulatory role by associating with cellular tyrosine kinases, transcription factors, and glucocorticoid receptors. Hsp27 suppresses protein aggregation.

Hsp70 heat shock proteins are a member of extracellular and membrane bound heat-shock proteins which are involved in binding antigens and presenting them to the immune system. Hsp70 has been found to inhibit the activity of influenza A virus ribonucleoprotein and to block the replication of the virus. Heat shock proteins derived from tumors elicit specific protective immunity. Experimental and clinical observations have shown that heat shock proteins are involved in the regulation of autoimmune arthritis, type 1 diabetes, mellitus, arterial sclerosis, multiple sclerosis, and other autoimmune reactions.

2

Accordingly, it is believed that it is advantageous to be able to selectively induce the heat shock response in order to increase the number or activity of heat shock proteins in body tissue in response to infection or other abnormalities. However, this must be done in a controlled manner in order not to damage or destroy the tissue or the area of the body being treated. The present invention fulfills these needs, and provides other related advantages.

SUMMARY OF THE INVENTION

The present invention is directed to a method for stimulating heat shock protein activation in tissue without damaging the target tissue. The method comprises the steps of providing a source of pulsed ultrasound or electromagnetic energy. The electromagnetic energy may comprise ultraviolet waves, microwaves, radio frequency waves or laser light at a predetermined wavelength. The laser light may have a wavelength between 530 nm to 1300 nm, a duty cycle of less than 10% and a pulse length of 500 milliseconds or less.

The pulsed ultrasound or electromagnetic radiation energy is applied to the target tissue to create a thermal time-course that stimulates cells of the target tissue to activate heat shock proteins without damaging the target tissue. This includes raising the target tissue temperature to at least 10° C. transiently, while only 1° C. or less over several minutes.

In one embodiment, a plurality of laser light spots are simultaneously applied to the target tissue. In another embodiment, a plurality of ultrasound beams are focused on the target tissue.

A device may be inserted into a cavity of the body in order to apply the pulsed ultrasound or electromagnetic radiation energy to the tissue. The device may comprise an endoscope.

The pulsed ultrasound or electromagnetic radiation energy may be applied to an exterior area of a body which is adjacent to the target tissue, or has a blood supply close to a surface of the exterior area of the body. For example, the body area may comprise an earlobe and the pulse electromagnetic radiation energy is applied to the blood flowing through the earlobe.

Other features and advantages of the present invention will become apparent from the following more detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings illustrate the invention. In such drawings:

FIG. 1 is a diagrammatic view of a light generating unit that produces timed series of pulses, having a light pipe extending therefrom, in accordance with the present invention;

FIG. 2 is a cross-sectional view of a photostimulation delivery device delivering electromagnetic energy to target tissue, in accordance with the present invention;

FIG. 3 is a diagrammatic view illustrating a system used to generate a laser light beam, in accordance with the present invention;

FIG. 4 is a diagrammatic view of optics used to generate a laser light geometric pattern, in accordance with the present invention;

FIG. 5 is a diagrammatic view illustrating an alternate embodiment of the system used to generate laser light beams for treating tissue, in accordance with the present invention;

FIG. 6 is a diagrammatic view illustrating yet another embodiment of a system used to generate laser light beams to treat tissue in accordance with the present invention;

FIG. 7 is a cross-sectional and diagrammatic view of an end of an endoscope inserted into the nasal cavity and treating tissue therein, in accordance with the present invention;

FIG. 8 is a diagrammatic and partially cross-sectioned view of a bronchoscope extending through the trachea and into the bronchus of a lung and providing treatment thereto, in accordance with the present invention;

FIG. 9 is a diagrammatic view of a colonoscope providing photostimulation to an intestinal or colon area of the body, in accordance with the present invention;

FIG. 10 is a diagrammatic view of an endoscope inserted into a stomach and providing treatment thereto, in accordance with the present invention;

FIG. 11 is a partially sectioned perspective view of a capsule endoscope, used in accordance with the present invention;

FIG. 12 is a diagrammatic view of a pulsed high intensity focused ultrasound for treating tissue internal the body, in accordance with the present invention;

FIG. 13 is a diagrammatic view for delivering therapy to the bloodstream of a patient, through an earlobe, in accordance with the present invention;

FIG. 14 is a cross-sectional view of a stimulating therapy device of the present invention used in delivering photostimulation to the blood, via an earlobe, in accordance with the present invention.

FIG. 15 is a graph comparing equations for temperature over pulse durations, in accordance with the present invention; and

FIGS. 16 and 17 are graphs illustrating the magnitude of the algorithm of damage and HSP activation Arrhenius integrals as a function of temperature and pulse duration.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As shown in the accompanying drawings, and as more fully described herein, the present invention is directed to a system and method for delivering an energy source, such as laser, ultrasound, ultraviolet radiofrequency, microwave radiofrequency and the like, to cause a pulsing thermal time-course in tissue that stimulates heat shock protein activation or production and facilitates protein repair without causing any damage.

The inventors of the present invention have discovered that applying electromagnetic radiation, in the form of various wavelengths of laser light, to retinal tissue in a manner that does not destroy or damage the retinal tissue has achieved beneficial effects on eye diseases. It is believed that this may be due, at least in part, to the stimulation and activation of heat shock proteins and the facilitation of protein repair in the retinal tissue. This is disclosed in U.S. patent application Ser. No. 14/607,959 filed Jan. 28, 2015, Ser. No. 13/798,523 filed Mar. 13, 2013, and Ser. No. 13/481,124 filed May 25, 2012, the contents of which are hereby incorporated by reference as if made in full.

The inventors have found that a laser light beam can be generated that is therapeutic, yet sublethal to retinal tissue cells and thus avoids damaging photocoagulation in the retinal tissue which provides preventative and protective treatment of the retinal tissue of the eye. The inventors have discovered that generating a subthreshold, sublethal micropulse laser light beam which has a wavelength greater than

532 nm and a duty cycle of less than 10% at a predetermined intensity or power and a predetermined pulse length or exposure time creates desirable retinal photostimulation without any visible burn areas or tissue destruction. More particularly, a laser light beam having a wavelength of between 550 nm-1300 nm, and in a particularly preferred embodiment 810 nm, having a duty cycle of approximately 5% or less and a predetermined intensity or power (such as between 100-590 watts per square centimeter at the retina or approximately 1 watt per laser spot for each treatment spot at the retina) and a predetermined pulse length or exposure time (such as 500 milliseconds or less) creates a sublethal, "true subthreshold" retinal photostimulation in which all areas of the retinal pigment epithelium exposed to the laser irradiation are preserved and available to contribute therapeutically. In other words, the inventors have found that raising the retinal tissue at least up to a therapeutic level but below a cellular or tissue lethal level recreates the benefit of the halo effect of the prior art methods without destroying, burning or otherwise damaging the retinal tissue. This is referred to herein as subthreshold diode micropulse laser treatment (SDM).

As SDM does not produce laser-induced retinal damage (photocoagulation), and has no known adverse treatment effect, and has been reported to be an effective treatment in a number of retinal disorders (including diabetic macular edema (DME) proliferative diabetic retinopathy (PDR), macular edema due to branch retinal vein occlusion (BRVO), central serous chorioretinopathy (CSR), reversal of drug tolerance, and prophylactic treatment of progressive degenerative retinopathies such as dry age-related macular degeneration, Stargardt's disease, cone dystrophies, and retinitis pigmentosa. The safety of SDM is such that it may be used transfoveally in eyes with 20/20 visual acuity to reduce the risk of visual loss due to early fovea-involving DME.

A mechanism through which SDM might work is the generation or activation of heat shock proteins (HSPs). Despite a near infinite variety of possible cellular abnormalities, cells of all types share a common and highly conserved mechanism of repair: heat shock proteins (HSPs). HSPs are elicited almost immediately, in seconds to minutes, by almost any type of cell stress or injury. In the absence of lethal cell injury, HSPs are extremely effective at repairing and returning the viable cell toward a more normal functional state. Although HSPs are transient, generally peaking in hours and persisting for a few days, their effects may be long lasting. HSPs reduce inflammation, a common factor in many disorders.

Laser treatment can induce HSP production or activation and alter cytokine expression. The more sudden and severe the non-lethal cellular stress (such as laser irradiation), the more rapid and robust HSP activation. Thus, a burst of repetitive low temperature thermal spikes at a very steep rate of change ($\sim 7^\circ \text{C.}$ elevation with each 100 μs micropulse, or 70,000 $^\circ \text{C./sec}$) produced by each SDM exposure is especially effective in stimulating activation of HSPs, particularly compared to non-lethal exposure to subthreshold treatment with continuous wave lasers, which can duplicate only the low average tissue temperature rise.

Laser wavelengths below 550 nm produce increasingly cytotoxic photochemical effects. At 810 nm, SDM produces photothermal, rather than photochemical, cellular stress. Thus, SDM is able to affect the tissue without damaging it. The clinical benefits of SDM are thus primarily produced by sub-morbid photothermal cellular HSP activation. In dysfunctional cells, HSP stimulation by SDM results in nor-

malized cytokine expression, and consequently improved structure and function. The therapeutic effects of this “low-intensity” laser/tissue interaction are then amplified by “high-density” laser application, recruiting all the dysfunctional cells in the targeted tissue area by densely/confluently treating a large tissue area, including all areas of pathology, thereby maximizing the treatment effect. These principles define the treatment strategy of SDM described herein.

Because normally functioning cells are not in need of repair, HSP stimulation in normal cells would tend to have no notable clinical effect. The “patho-selectivity” of near infrared laser effects, such as SDM, affecting sick cells but not affecting normal ones, on various cell types is consistent with clinical observations of SDM. SDM has been reported to have a clinically broad therapeutic range, unique among retinal laser modalities, consistent with American National Standards Institute “Maximum Permissible Exposure” predictions. While SDM may cause direct photothermal effects such as entropic protein unfolding and disaggregation, SDM appears optimized for clinically safe and effective stimulation of HSP-mediated repair.

As noted above, while SDM stimulation of HSPs is non-specific with regard to the disease process, the result of HSP mediated repair is by its nature specific to the state of the dysfunction. HSPs tend to fix what is wrong, whatever that might be. Thus, the observed effectiveness of SDM in retinal conditions as widely disparate as BRVO, DME, PDR, CSR, age-related and genetic retinopathies, and drug-tolerant NAMD. Conceptually, this facility can be considered a sort of “Reset to Default” mode of SDM action. For the wide range of disorders in which cellular function is critical, SDM normalizes cellular function by triggering a “reset” (to the “factory default settings”) via HSP-mediated cellular repair.

The inventors have found that SDM treatment of patients suffering from age-related macular degeneration (AMD) can slow the progress or even stop the progression of AMD. Most of the patients have seen significant improvement in dynamic functional log MAR mesopic visual acuity and mesopic contrast visual acuity after the SDM treatment. It is believed that SDM works by targeting, preserving, and “normalizing” (moving toward normal) function of the retinal pigment epithelium (RPE).

SDM has also been shown to stop or reverse the manifestations of the diabetic retinopathy disease state without treatment-associated damage or adverse effects, despite the persistence of systemic diabetes mellitus. On this basis it is hypothesized that SDM might work by inducing a return to more normal cell function and cytokine expression in diabetes-affected RPE cells, analogous to hitting the “reset” button of an electronic device to restore the factory default settings. Based on the above information and studies, SDM treatment may directly affect cytokine expression via heat shock protein (HSP) activation in the targeted tissue.

As heat shock proteins play a role in responding to a large number of abnormal conditions in body tissue other than eye tissue, it is believed that similar systems and methodologies can be advantageously used in treating such abnormal conditions, infections, etc. As such, the present invention is directed to the controlled application of ultrasound or electromagnetic radiation to treat abnormal conditions including inflammations, autoimmune conditions, and cancers that are accessible by means of fiber optics of endoscopes or surface probes as well as focused electromagnetic/sound waves. For example, cancers on the surface of the prostate that have the largest threat of metastasizing can be accessed by means of fiber optics in a proctoscope. Colon tumors can be accessed by an optical fiber system, like those used in colonoscopy.

As indicated above, subthreshold diode micropulse laser (SDM) photostimulation has been effective in stimulating direct repair of slightly misfolded proteins in eye tissue. Besides HSP activation, another way this may occur is because the spikes in temperature caused by the micropulses in the form of a thermal time-course allows diffusion of water inside proteins, and this allows breakage of the peptide-peptide hydrogen bonds that prevent the protein from returning to its native state. The diffusion of water into proteins results in an increase in the number of restraining hydrogen bonds by a factor on the order of a thousand. Thus, it is believed that this process could be applied to other diseases advantageously as well.

Photostimulation, in accordance with the present invention, can be effectively transmitted to an internal surface area or tissue of the body utilizing an endoscope, such as a bronchoscope, proctoscope, colonoscope or the like. Each of these consist essentially of a flexible tube that itself contains one or more internal tubes. Typically, one of the internal tubes comprises a light pipe or multi-mode optical fiber which conducts light down the scope to illuminate the region of interest and enable the doctor to see what is at the illuminated end. Another internal tube could consist of wires that carry an electrical current to enable the doctor to cauterize the illuminated tissue. Yet another internal tube might consist of a biopsy tool that would enable the doctor to snip off and hold on to any of the illuminated tissue.

In the present invention, one of these internal tubes is used as an electromagnetic radiation pipe, such as a multi-mode optical fiber, to transmit the SDM or other electromagnetic radiation pulses that are fed into the scope at the end that the doctor holds. With reference now to FIG. 1, a light generating unit 10, such as a laser having a desired wavelength and/or frequency is used to generate electromagnetic radiation, such as laser light, in a controlled, pulsed manner to be delivered through a light tube or pipe 12 to a distal end of the scope 14, illustrated in FIG. 2, which is inserted into the body and the laser light or other radiation 16 delivered to the target tissue 18 to be treated.

With reference now to FIG. 3, a schematic diagram is shown of a system for generating electromagnetic energy radiation, such as laser light, including SDM. The system, generally referred to by the reference number 20, includes a laser console 22, such as for example the 810 nm near infrared micropulsed diode laser in the preferred embodiment. The laser generates a laser light beam which is passed through optics, such as an optical lens or mask, or a plurality of optical lenses and/or masks 24 as needed. The laser projector optics 24 pass the shaped light beam to a delivery device 26, such as an endoscope, for projecting the laser beam light onto the target tissue of the patient. It will be understood that the box labeled 26 can represent both the laser beam projector or delivery device as well as a viewing system/camera, such as an endoscope, or comprise two different components in use. The viewing system/camera 26 provides feedback to a display monitor 28, which may also include the necessary computerized hardware, data input and controls, etc. for manipulating the laser 22, the optics 24, and/or the projection/viewing components 26.

With reference now to FIG. 4, in one embodiment, the laser light beam 30 may be passed through a collimator lens 32 and then through a mask 34. In a particularly preferred embodiment, the mask 34 comprises a diffraction grating. The mask/diffraction grating 34 produces a geometric object, or more typically a geometric pattern of simultaneously produced multiple laser spots or other geometric objects. This is represented by the multiple laser light beams

labeled with reference number **36**. Alternatively, the multiple laser spots may be generated by a plurality of fiber optic waveguides. Either method of generating laser spots allows for the creation of a very large number of laser spots simultaneously over a very wide treatment field. In fact, a very high number of laser spots, perhaps numbering in the hundreds even thousands or more could be simultaneously generated to cover a given area of the target tissue, or possibly even the entirety of the target tissue. A wide array of simultaneously applied small separated laser spot applications may be desirable as such avoids certain disadvantages and treatment risks known to be associated with large laser spot applications.

Using optical features with a feature size on par with the wavelength of the laser employed, for example using a diffraction grating, it is possible to take advantage of quantum mechanical effects which permits simultaneous application of a very large number of laser spots for a very large target area. The individual spots produced by such diffraction gratings are all of a similar optical geometry to the input beam, with minimal power variation for each spot. The result is a plurality of laser spots with adequate irradiance to produce harmless yet effective treatment application, simultaneously over a large target area. The present invention also contemplates the use of other geometric objects and patterns generated by other diffractive optical elements.

The laser light passing through the mask **34** diffracts, producing a periodic pattern a distance away from the mask **34**, shown by the laser beams labeled **36** in FIG. **4**. The single laser beam **30** has thus been formed into hundreds or even thousands of individual laser beams **36** so as to create the desired pattern of spots or other geometric objects. These laser beams **36** may be passed through additional lenses, collimators, etc. **38** and **40** in order to convey the laser beams and form the desired pattern. Such additional lenses, collimators, etc. **38** and **40** can further transform and redirect the laser beams **36** as needed.

Arbitrary patterns can be constructed by controlling the shape, spacing and pattern of the optical mask **34**. The pattern and exposure spots can be created and modified arbitrarily as desired according to application requirements by experts in the field of optical engineering. Photolithographic techniques, especially those developed in the field of semiconductor manufacturing, can be used to create the simultaneous geometric pattern of spots or other objects.

FIG. **5** illustrates diagrammatically a system which couples multiple light sources into the pattern-generating optical subassembly described above. Specifically, this system **20'** is similar to the system **20** described in FIG. **3** above. The primary differences between the alternate system **20'** and the earlier described system **20** is the inclusion of a plurality of laser consoles, the outputs of which are each fed into a fiber coupler **42**. The fiber coupler produces a single output that is passed into the laser projector optics **24** as described in the earlier system. The coupling of the plurality of laser consoles **22** into a single optical fiber is achieved with a fiber coupler **42** as is known in the art. Other known mechanisms for combining multiple light sources are available and may be used to replace the fiber coupler described herein.

In this system **20'** the multiple light sources **22** follow a similar path as described in the earlier system **20**, i.e., collimated, diffracted, recollimated, and directed to the projector device and/or tissue. In this alternate system **20'** the diffractive element must function differently than described earlier depending upon the wavelength of light passing through, which results in a slightly varying pattern. The

variation is linear with the wavelength of the light source being diffracted. In general, the difference in the diffraction angles is small enough that the different, overlapping patterns may be directed along the same optical path through the projector device **26** to the tissue for treatment.

Since the resulting pattern will vary slightly for each wavelength, a sequential offsetting to achieve complete coverage will be different for each wavelength. This sequential offsetting can be accomplished in two modes. In the first mode, all wavelengths of light are applied simultaneously without identical coverage. An offsetting steering pattern to achieve complete coverage for one of the multiple wavelengths is used. Thus, while the light of the selected wavelength achieves complete coverage of the tissue, the application of the other wavelengths achieves either incomplete or overlapping coverage of the tissue. The second mode sequentially applies each light source of a varying wavelength with the proper steering pattern to achieve complete coverage of the tissue for that particular wavelength. This mode excludes the possibility of simultaneous treatment using multiple wavelengths, but allows the optical method to achieve identical coverage for each wavelength. This avoids either incomplete or overlapping coverage for any of the optical wavelengths.

These modes may also be mixed and matched. For example, two wavelengths may be applied simultaneously with one wavelength achieving complete coverage and the other achieving incomplete or overlapping coverage, followed by a third wavelength applied sequentially and achieving complete coverage.

FIG. **6** illustrates diagrammatically yet another alternate embodiment of the inventive system **20''**. This system **20''** is configured generally the same as the system **20** depicted in FIG. **3**. The main difference resides in the inclusion of multiple pattern-generating subassembly channels tuned to a specific wavelength of the light source. Multiple laser consoles **22** are arranged in parallel with each one leading directly into its own laser projector optics **24**. The laser projector optics of each channel **44a**, **44b**, **44c** comprise a collimator **32**, mask or diffraction grating **34** and recollimators **38**, **40** as described in connection with FIG. **4** above—the entire set of optics tuned for the specific wavelength generated by the corresponding laser console **22**. The output from each set of optics **24** is then directed to a beam splitter **46** for combination with the other wavelengths. It is known by those skilled in the art that a beam splitter used in reverse can be used to combine multiple beams of light into a single output.

The combined channel output from the final beam splitter **46c** is then directed through the projector device **26**.

In this system **20''** the optical elements for each channel are tuned to produce the exact specified pattern for that channel's wavelength. Consequently, when all channels are combined and properly aligned a single steering pattern may be used to achieve complete coverage of the tissue for all wavelengths.

The system **20''** may use as many channels **44a**, **44b**, **44c**, etc. and beam splitters **46a**, **46b**, **46c**, etc. as there are wavelengths of light being used in the treatment.

Implementation of the system **20''** may take advantage of different symmetries to reduce the number of alignment constraints. For example, the proposed grid patterns are periodic in two dimensions and steered in two dimensions to achieve complete coverage. As a result, if the patterns for each channel are identical as specified, the actual pattern of each channel would not need to be aligned for the same steering pattern to achieve complete coverage for all wave-

lengths. Each channel would only need to be aligned optically to achieve an efficient combination.

In system **20**", each channel begins with a light source **22**, which could be from an optical fiber as in other embodiments of the pattern-generating subassembly. This light source **22** is directed to the optical assembly **24** for collimation, diffraction, recollimation and directed into the beam splitter which combines the channel with the main output.

It will be understood that the laser light generating systems illustrated in FIGS. **3-6** are exemplary. Other devices and systems can be utilized to generate a source of SDM laser light which can be operably passed through to a projector device, typically in the form of an endoscope having a light pipe or the like. Other forms of electromagnetic radiation may also be generated and used, including ultraviolet waves, microwaves, other radiofrequency waves, and laser light at predetermined wavelengths. Moreover, ultrasound waves may also be generated and used to create a thermal time-course temperature spike in the target tissue sufficient to activate or produce heat shock proteins in the cells of the target tissue without damaging the target tissue itself. In order to do so, typically, a pulsed source of ultrasound or electromagnetic radiation energy is provided and applied to the target tissue in a manner which raises the target tissue temperature, such as at least 10° C., transiently while only 1° C. or less for the long term, such as over several minutes, such as two or more minutes.

For deep tissue that is not near an internal orifice, a light pipe is not an effective means of delivering the pulsed energy. In that case, pulsed low frequency electromagnetic energy or preferably pulsed ultrasound can be used to cause a series of temperature spikes in the target tissue.

Thus, in accordance with the present invention, a source of pulsed ultrasound or electromagnetic radiation is applied to the target tissue in order to stimulate HSP production or activation and to facilitate protein repair in the living animal tissue. In general, Electromagnetic radiation may be ultraviolet waves, microwaves, other radiofrequency waves, laser light at predetermined wavelengths, etc. On the other hand, if electromagnetic energy is to be used for deep tissue targets away from natural orifices, absorption lengths restrict the wavelengths to those of microwaves or radiofrequency waves, depending on the depth of the target tissue. However, as explained later, ultrasound is to be preferred to long wavelength electromagnetic radiation for deep tissue targets away from natural orifices.

The ultrasound or electromagnetic radiation is pulsed so as to create a thermal time-course in the tissue that stimulates HSP production or activation and facilitates protein repair without causing damage to the cells and tissue being treated. The area and/or volume of the treated tissue is also controlled and minimized so that the temperature spikes are on the order of several degrees, e.g. approximately 10° C., while maintaining the long-term rise in temperature to be less than the FDA mandated limit of 1° C. It has been found that if too large of an area or volume of tissue is treated, the increased temperature of the tissue cannot be diffused sufficiently quickly enough to meet the FDA requirements. However, limiting the area and/or volume of the treated tissue as well as creating a pulsed source of energy accomplishes the goals of the present invention of stimulating HSP activation or production by heating or otherwise stressing the cells and tissue, while allowing the treated cells and tissues to dissipate any excess heat generated to within acceptable limits.

It is believed that stimulating HSP production in accordance with the present invention can be effectively utilized

in treating a wide array of tissue abnormalities, ailments, and even infections. For example, the viruses that cause colds primarily affect a small part of the respiratory epithelium in the nasal passages and nasopharynx. Similar to the retina, the respiratory epithelium is a thin and clear tissue. With reference to FIG. **7**, a cross-sectional view of a human head **48** is shown with an endoscope **14** inserted into the nasal cavity **50** and energy **16**, such as laser light or the like, being directed to tissue **18** to be treated within the nasal cavity **50**. The tissue **18** to be treated could be within the nasal cavity **50**, including the nasal passages, and nasopharynx.

To assure absorption of the laser energy, or other energy source, the wavelength can be adjusted to an infrared (IR) absorption peak of water, or an adjuvant dye can be used to serve as a photosensitizer. In such a case, treatment would then consist of drinking, or topically applying, the adjuvant, waiting a few minutes for the adjuvant to permeate the surface tissue, and then administering the laser light or other energy source **16** to the target tissue **18** for a few seconds, such as via optical fibers in an endoscope **14**, as illustrated in FIG. **7**. To provide comfort of the patient, the endoscope **14** could be inserted after application of a topical anesthetic. If necessary, the procedure could be repeated periodically, such as in a day or so.

As discussed above, the treatment would stimulate the activation or production of heat shock proteins and facilitate protein repair without damaging the cells and tissues being treated. As discussed above, certain heat shock proteins have been found to play an important role in the immune response as well as the well-being of the targeted cells and tissue. The source of energy could be monochromatic laser light, such as 810 nm wavelength laser light, administered in a manner similar to that described in the above-referenced patent applications, but administered through an endoscope or the like, as illustrated in FIG. **7**. The adjuvant dye would be selected so as to increase the laser light absorption. While this comprises a particularly preferred method and embodiment of performing the invention, it will be appreciated that other types of energy and delivery means could be used to achieve the same objectives in accordance with the present invention.

With reference now to FIG. **8**, a similar situation exists for the flu virus, where the primary target is the epithelium of the upper respiratory tree, in segments that have diameters greater than about 3.3 mm, namely, the upper six generations of the upper respiratory tree. A thin layer of mucous separates the targeted epithelial cells from the airway lumen, and it is in this layer that the antigen-antibody interactions occur that result in inactivation of the virus.

With continuing reference to FIG. **8**, the flexible light tube **12** of a bronchoscope **14** is inserted through the individual's mouth **52** through the throat and trachea **54** and into a bronchus **56** of the respiratory tree. There the laser light or other energy source **16** is administered and delivered to the tissue in this area of the uppermost segments to treat the tissue and area in the same manner described above with respect to FIG. **7**. It is contemplated that a wavelength of laser or other energy would be selected so as to match an IR absorption peak of the water resident in the mucous to heat the tissue and stimulate HSP activation or production and facilitate protein repair, with its attendant benefits.

With reference now to FIG. **9**, a colonoscope **14** could have flexible optical tube **12** thereof inserted into the anus and rectum **58** and into either the large intestine **60** or small intestine **62** so as to deliver the selected laser light or other energy source **16** to the area and tissue to be treated, as

11

illustrated. This could be used to assist in treating colon cancer as well as other gastrointestinal issues.

Typically, the procedure could be performed similar to a colonoscopy in that the bowel would be cleared of all stool, and the patient would lie on his/her side and the physician would insert the long, thin light tube portion **12** of the colonoscope **14** into the rectum and move it into the area of the colon, large intestine **60** or small intestine **64** to the area to be treated. The physician could view through a monitor the pathway of the inserted flexible member **12** and even view the tissue at the tip of the colonoscope **14** within the intestine, so as to view the area to be treated. Using one of the other fiber optic or light tubes, the tip **64** of the scope would be directed to the tissue to be treated and the source of laser light or other radiation **16** would be delivered through one of the light tubes of the colonoscope **14** to treat the area of tissue to be treated, as described above, in order to stimulate HSP activation or production in that tissue **18**.

With reference now to FIG. **10**, another example in which the present invention can be advantageously used is what is frequently referred to as "leaky gut" syndrome, a condition of the gastrointestinal (GI) tract marked by inflammation and other metabolic dysfunction. Since the GI tract is susceptible to metabolic dysfunction similar to the retina, it is anticipated that it will respond well to the treatment of the present invention. This could be done by means of sub-threshold, diode micropulse laser (SDM) treatment, as discussed above, or by other energy sources and means as discussed herein and known in the art.

With continuing reference to FIG. **10**, the flexible light tube **12** of an endoscope or the like is inserted through the patient's mouth **52** through the throat and trachea area **54** and into the stomach **66**, where the tip or end **64** thereof is directed towards the tissue **18** to be treated, and the laser light or other energy source **16** is directed to the tissue **18**. It will be appreciated by those skilled in the art that a colonoscope could also be used and inserted through the rectum **58** and into the stomach **66** or any tissue between the stomach and the rectum.

If necessary, a chromophore pigment could be delivered to the GI tissue orally to enable absorption of the radiation. If, for instance, unfocused 810 nm radiation from a laser diode or LED were to be used, the pigment would have an absorption peak at or near 810 nm. Alternatively, the wavelength of the energy source could be adjusted to a slightly longer wavelength at an absorption peak of water, so that no externally applied chromophore would be required.

It is also contemplated by the present invention that a capsule endoscope **68**, such as that illustrated in FIG. **11**, could be used to administer the radiation and energy source in accordance with the present invention. Such capsules are relatively small in size, such as approximately one inch in length, so as to be swallowed by the patient. As the capsule or pill **68** is swallowed and enters into the stomach and passes through the GI tract, when at the appropriate location, the capsule or pill **68** could receive power and signals, such as via antenna **70**, so as to activate the source of energy **72**, such as a laser diode and related circuitry, with an appropriate lens **74** focusing the generated laser light or radiation through a radiation-transparent cover **76** and onto the tissue to be treated. It will be understood that the location of the capsule endoscope **68** could be determined by a variety of means such as external imaging, signal tracking, or even by means of a miniature camera with lights through which the doctor would view images of the GI tract through which the pill or capsule **68** was passing through at the time. The capsule or pill **68** could be supplied with its own power

12

source, such as by virtue of a battery, or could be powered externally via an antenna, such that the laser diode **72** or other energy generating source create the desired wavelength and pulsed energy source to treat the tissue and area to be treated.

As in the treatment of the retina in previous applications, the radiation would be pulsed to take advantage of the micropulse temperature spikes and associated safety, and the power could be adjusted so that the treatment would be completely harmless to the tissue. This could involve adjusting the peak power, pulse times, and repetition rate to give spike temperature rises on the order of 10° C., while maintaining the long term rise in temperature to be less than the FDA mandated limit of 1° C. If the pill form **68** of delivery is used, the device could be powered by a small rechargeable battery or over wireless inductive excitation or the like. The heated/stressed tissue would stimulate activation or production of HSP and facilitate protein repair, and the attendant benefits thereof.

From the foregoing examples, the technique of the present invention is limited to the treatment of conditions at near body surfaces or at internal surfaces easily accessible by means of fiber optics or other optical delivery means. The reason that the application of SDM to activate HSP activity is limited to near surface or optically accessible regions of the body is that the absorption length of IR or visible radiation in the body is very short. However, there are conditions deeper within tissue or the body which could benefit from the present invention. Thus, the present invention contemplates the use of ultrasound and/or radio frequency (RF) and even shorter wavelength electromagnetic (EM) radiation which have relatively long absorption lengths in body tissue. As will be more fully described below, the use of pulsed ultrasound is preferable to RF electromagnetic radiation to activate remedial HSP activity in abnormal tissue that is inaccessible to surface SDM or the like. Pulsed ultrasound sources can also be used for abnormalities at or near surfaces as well.

With reference now to FIG. **12**, with ultrasound, a specific region deep in the body can be specifically targeted by using one or more beams that are each focused on the target site. The pulsating heating will then be largely only in the targeted region where the beams are focused and overlap.

As illustrated in FIG. **12**, an ultrasound transducer **78** or the like generates a plurality of ultrasound beams **80** which are coupled to the skin via an acoustic-impedance-matching gel, and penetrate through the skin **82** and through undamaged tissue in front of the focus of the beams **80** to a target organ **84**, such as the illustrated liver, and specifically to a target tissue **86** to be treated where the ultrasound beams **80** are focused. As mentioned above, the pulsating heating will then only be at the targeted, focused region **86** where the focused beams **80** overlap. The tissue in front of and behind the focused region **86** will not be heated or affected appreciably.

Examples of parameters giving a desired HSP activation Arrhenius integral greater than 1 and damage Arrhenius integral less than 1 is a total ultrasound power between 5.8-17 watts, a pulse duration of 0.5 seconds, an interval between pulses of 5 seconds, with total number of pulses **10** within the total pulse stream time of 50 seconds. The target treatment volume would be approximately 1 mm on a side. Larger treatment volumes could be treatable by an ultrasound system similar to the laser diffracted optical system (described in paragraph **45**), by applying ultrasound in multiple simultaneously applied adjacent but separated and spaced columns. As mentioned above, the multiple focused

ultrasound beams converge on a very small treatment target within the body, the convergence allowing for a minimal heating except at the overlapping beams at the target. This area would be heated and stimulate the activation of HSPs and facilitate protein repair by transient high temperature spikes. However, given the pulsating aspect of the invention as well as the relatively small area being treated at any given time, the treatment is in compliance with FDA/FCC requirements for long term (minutes) average temperature rise <1K. An important distinction of the invention from existing therapeutic heating treatments for pain and muscle strain is that there are no high T spikes in existing techniques, and these are required for efficiently activating HSPs and facilitating protein repair to provide healing at the cellular level.

The pulse train mode of energy delivery has a distinct advantage over a single pulse or gradual mode of energy delivery, as far as the activation of remedial HSPs and the facilitation of protein repair is concerned. There are two considerations that enter into this advantage:

First, a big advantage for HSP activation and protein repair in an SDM energy delivery mode comes from producing a spike temperature of the order of 10° C. This large rise in temperature has a big impact on the Arrhenius integrals that describe quantitatively the number of HSPs that are activated and the rate of water diffusion into the proteins that facilitates protein repair. This is because the temperature enters into an exponential that has a big amplification effect.

It is important that the temperature rise not remain at the high value (10+ degrees) for long, because then it would violate the FDA and FCC requirements that over periods of minutes the average temperature rise must be less than 1° C.

An SDM mode of energy delivery uniquely satisfies both of these foregoing considerations by judicious choice of the power, pulse time, pulse interval, and the volume of the target region to be treated. The volume of the treatment region enters because the temperature must decay from its high value of the order of 10° C. fairly rapidly in order for the long term average temperature rise not to exceed the long term FDA/FCC limit of 1° C.

For a region of linear dimension L, the time that it takes the peak temperature to e-fold in tissue is roughly $L^2/16D$, where $D=0.00143 \text{ cm}^2/\text{sec}$ is the typical heat diffusion coefficient. For example, if $L=1 \text{ mm}$, the decay time is roughly 0.4 sec. Accordingly, for a region 1 mm on a side, a train consisting of 10 pulses each of duration 0.5 seconds, with an interval between pulses of 5 second can achieve the desired momentary high rise in temperature while still not exceeding an average long term temperature rise of 1° C. This is demonstrated further below.

The limitation of heated volume is the reason why RF electromagnetic radiation is not as good of a choice for SDM-type treatment of regions deep with the body. The long skin depths (penetration distances) and Ohmic heating all along the skin depth results in a large heated volume whose thermal inertia does not allow both the attainment of a high spike temperature that activates HSPs and facilitates protein repair, and the rapid temperature decay that satisfies the long term FDA and FCC limit on average temperature rise.

Ultrasound has already been used to therapeutically heat regions of the body to ease pain and muscle strain. However, the heating has not followed the SDM-type protocol and does not have the temperature spikes that are responsible for the excitation of HSPs.

Consider, then, a group of focused ultrasound beams that are directed at a target region deep within the body. To simplify the mathematics, suppose that the beams are

replaced by a single source with a spherical surface shape that is focused on the center of the sphere. The absorption lengths of ultrasound can be fairly long. Table 1 below shows typical absorption coefficients for ultrasound at 1 MHz. The absorption coefficients are roughly proportional to the frequency.

TABLE 1

Typical absorption coefficients for 1 MHz ultrasound in body tissue:	
Body Tissue	Attenuation Coefficient at 1 MHz (cm^{-1})
Water	0.00046
Blood	0.0415
Fat	0.145
Liver	0.115-0.217
Kidney	0.23
Muscle	0.3-0.76
Bone	1.15

Assuming that the geometric variation of the incoming radiation due to the focusing dominates any variation due to attenuation, the intensity of the incoming ultrasound at a distance r from the focus can be written approximately as:

$$I(r)=P/(4\pi r^2) \quad [1]$$

where P denotes the total ultrasound power.

The temperature rise at the end of a short pulse of duration t_p at r is then

$$dT(t_p)=P\alpha t_p/(4\pi C_v r^2) \quad [2]$$

where α is the absorption coefficient and C_v is the specific volume heat capacity. This will be the case until the r is reached at which the heat diffusion length at t_p becomes comparable to r, or the diffraction limit of the focused beam is reached. For smaller r, the temperature rise is essentially independent of r. As an example, suppose the diffraction limit is reached at a radial distance that is smaller than that determined by heat diffusion. Then

$$r_{dif}=(4Dt_p)^{1/2} \quad [3]$$

where D is the heat diffusion coefficient, and for $r<r_{dif}$, the temperature rise at t_p is

$$dT(r_{dif},t_p)=3P\alpha/(8\pi C_v D) \text{ when } r<r_{dif} \quad [4]$$

Thus, at the end of the pulse, we can write for the temperature rise:

$$dT_p(r)=\{P\alpha t_p/(4\pi C_v)\}[(6/r_{dif}^2)U\{r_{dif}/r\}+(1/r^2)U(r-r_{dif})] \quad [5]$$

On applying the Green's function for the heat diffusion equation,

$$G(r,t)=(4\Omega Dt)^{-3/2}\exp[-r^2/(4Dt)] \quad [6]$$

to this initial temperature distribution, we find that the temperature $dT(t)$ at the focal point $r=0$ at a time t is

$$dT(t)=[dT_o\{(\frac{1}{2})+(\pi^{1/2}/6)\}][(\frac{1}{2})(t_p/t)^{3/2}+(\pi^{1/2}/6)(t_p/t)] \quad [7]$$

with

$$dT_o=3P\alpha/(8\pi C_v D) \quad [8]$$

A good approximation to eq. [7] is provided by:

$$dT(t)\approx dT_o(t_p/t)^{3/2} \quad [9]$$

as can be seen in FIG. 15, which is a comparison of eqs. [7] and [9] for $dT(t)/dT_o$ at the target treatment zone. The bottom curve is the approximate expression of eq [9].

15

The Arrhenius integral for a train of N pulses can now be evaluated with the temperature rise given by eq. [9]. In this expression,

$$dT_N(t) = \sum dT(t - nt_f) \quad [11]$$

where $dT(t - nt_f)$ is the expression of eq. [9] with t replaced by $t - nt_f$ and with t_f designating the interval between pulses.

The Arrhenius integral can be evaluated approximately by dividing the integration interval into the portion where the temperature spikes occur and the portion where the temperature spike is absent. The summation over the temperature spike contribution can be simplified by applying Laplace's end point formula to the integral over the temperature spike. In addition, the integral over the portion when the spikes are absent can be simplified by noting that the non-spike temperature rise very rapidly reaches an asymptotic value, so that a good approximation is obtained by replacing the varying time rise by its asymptotic value. When these approximations are made, eq. [10] becomes:

$$\Omega = AN \left[\left\{ t_p (2k_B T_o^2 / (3EdT_o)) \exp[-(E/k_B)1/(T_o + dT_o + dT_N(Nt_f))] \right\} + \exp[-(E/k_B)1/(T_o + dT_N(Nt_f))] \right] \quad [12]$$

where

$$dT_N(Nt_f) \approx 2.5 dT_o (t_p/t_f)^{3/2} \quad [13]$$

(The 2.5 in eq. [13] arises from the summation over n of $(N - n)^{-3/2}$ and is the magnitude of the harmonic number $(N, 3/2)$ for typical N of interest.)

It is interesting to compare this expression with that for SDM applied to the retina. The first term is very similar to that from the spike contribution in the retina case, except that the effective spike interval is reduced by a factor of 3 for this 3D converging beam case. The second term, involving $dT_N(Nt_f)$ is much smaller than in the retina case. There the background temperature rise was comparable in magnitude to the spike temperature rise. But here in the converging beam case, the background temperature rise is much smaller by the ratio $(t_p/t_f)^{3/2}$. This points up the importance of the spike contribution to the activation or production of HSP's and the facilitation of protein repair, as the background temperature rise which is similar to the rise in a continuous ultrasound heating case is insignificant compared to the spike contribution. At the end of the pulse train, even this low background temperature rise rapidly disappears by heat diffusion.

FIGS. 16 and 17 show the magnitude of the logarithm of the Arrhenius integrals for damage and for HSP activation or production as a function of dT_o for a pulse duration $t_p = 0.5$ sec, pulse interval $t_f = 10$ sec, and total number of pulses $N = 10$. Logarithm of Arrhenius integrals [eq. 12] for damage and for HSP activation as a function of the temperature rise in degrees Kelvin from a single pulse dT_o , for a pulse duration $t_p = 0.5$ sec., pulse interval $t_f = 10$ sec., and a total number of ultrasound pulses $N = 10$. FIG. 16 shows the logarithm of the damage integral with the Arrhenius constants $A = 8.71 \times 10^{33} \text{ sec}^{-1}$ and $E = 3.55 \times 10^{-12} \text{ ergs}$. FIG. 17 shows the logarithm of the HSP activation integral with the Arrhenius constants $A = 1.24 \times 10^{27} \text{ sec}^{-1}$ and $E = 2.66 \times 10^{-12} \text{ ergs}$. FIGS. 16 and 17 show that Ω_{damage} does not exceed 1 until dT_o exceeds 11.3 K, whereas Ω_{hsp} is greater than 1 over the whole interval shown, the desired condition for cellular repair without damage.

Equation [8] shows that when $\alpha = 0.1 \text{ cm}^{-1}$, a dT_o of 11.5 K can be achieved with a total ultrasound power of 5.8 watts. This is easily achievable. If α is increased by a factor of 2 or 3, the resulting power is still easily achievable. The volume of the region where the temperature rise is constant

16

(i.e. the volume corresponding to $r = r_d = (4Dt_p)^{1/2}$) is 0.00064 cc. This corresponds to a cube that is 0.86 mm on a side.

This simple example demonstrates that focused ultrasound should be usable to stimulate reparative HSP's deep in the body with easily attainable equipment:

Total ultrasound power:	5.8 watts-17 watts
Pulse time	0.5 sec
Pulse interval	5 sec
Total train duration (N = 10)	50 sec

To expedite the treatment of larger internal volumes, a SAPRA system can be used.

The present invention contemplates not only the treatment of surface or near surface tissue, such as using the laser light or the like, deep tissue using, for example, focused ultrasound beams or the like, but also treatment of blood diseases, such as sepsis. As indicated above, focused ultrasound treatment could be used both at surface as well as deep body tissue, and could also be applied in this case in treating blood. However, it is also contemplated that the SDM and similar treatment options which are typically limited to surface or near surface treatment of epithelial cells and the like be used in treating blood diseases at areas where the blood is accessible through a relatively thin layer of tissue, such as the earlobe.

With reference now to FIGS. 13 and 14, treatment of blood disorders simply requires the transmission of SDM or other electromagnetic radiation or ultrasound pulses to the earlobe 88, where the SDM or other radiation source of energy could pass through the earlobe tissue and into the blood which passes through the earlobe. It would be appreciated that this approach could also take place at other areas of the body where the blood flow is relatively high and/or near the tissue surface, such as fingertips, inside of the mouth or throat, etc.

With reference now to FIGS. 13 and 14, an earlobe 88 is shown adjacent to a clamp device 90 configured to transmit SDM radiation or the like. This could be, for example, by means of one or more laser diodes 92 which would transmit the desired frequency at the desired pulse and pulse train to the earlobe 88. Power could be provided, for example, by means of a lamp drive 94. Alternatively, the lamp drive 94 could be the actual source of laser light, which would be transmitted through the appropriate optics and electronics to the earlobe 88. The clamp device 90 would merely be used to clamp onto the patient's earlobe and cause that the radiation be constrained to the patient's earlobe 88. This may be by means of mirrors, reflectors, diffusers, etc. This could be controlled by a control computer 96, which would be operated by a keyboard 98 or the like. The system may also include a display and speakers 100, if needed, for example if the procedure were to be performed by an operator at a distance from the patient.

The proposed treatment with a train of electromagnetic or ultrasound pulses has two major advantages over earlier treatments that incorporate a single short or sustained (long) pulse. First, the short (preferably subsecond) individual pulses in the train activate cellular reset mechanisms like HSP activation with larger reaction rate constants than those operating at longer (minute or hour) time scales. Secondly, the repeated pulses in the treatment provide large thermal spikes (on the order of 10,000) that allow the cell's repair system to more rapidly surmount the activation energy barrier that separates a dysfunctional cellular state from the desired functional state. The net result is a "lowered thera-

17

peutic threshold” in the sense that a lower applied average power and total applied energy can be used to achieve the desired treatment goal.

Although several embodiments have been described in detail for purposes of illustration, various modifications may be made without departing from the scope and spirit of the invention. Accordingly, the invention is not to be limited, except as by the appended claims.

What is claimed is:

1. A method for stimulating heat shock protein activation in tissue, comprising the steps of:

providing a source of pulsed electromagnetic radiation energy comprising laser light having a wavelength of between 530 nm to 1300 nm, a duty cycle of less than 10% and a pulse length of 500 milliseconds or less; and applying the provided pulsed electromagnetic radiation energy to the target tissue to create a thermal time-course by raising the target tissue temperature up to approximately eleven degrees Celsius during application of the electromagnetic radiation energy, while maintaining the long term temperature rise of the target tissue to only one degree Celsius or less over several minutes to stimulate cells of the target tissue to activate heat shock proteins without damaging the target tissue.

2. The method of claim 1, wherein a plurality of laser light spots are simultaneously applied to the target tissue.

3. The method of claim 2, wherein the laser light has a power of approximately 1 watt per each treatment laser spot applied to the target tissue.

4. The method of claim 1, wherein the electromagnetic radiation energy applying step comprises the step of inserting a device into a cavity of a body and using the device to apply the pulsed electromagnetic radiation energy to the tissue.

5. The method of claim 4, wherein the device comprises an endoscope.

6. The method of claim 1, wherein the electromagnetic radiation energy applying step comprises the step of applying the pulsed electromagnetic radiation energy to an exterior area of a body which is adjacent to the target tissue or has a blood supply close to a surface of the exterior area of the body.

7. The method of claim 6, wherein the body area comprises an ear lobe and the pulsed electromagnetic radiation energy is applied to the blood flowing through the ear lobe to treat the blood.

18

8. The method of claim 1, wherein the laser light has a power of 100-590 watts per square centimeter of target tissue.

9. The method of claim 1, wherein target tissue temperature is raised approximately ten degrees Celsius during the application of the electromagnetic radiation energy.

10. A method for stimulating heat shock protein activation in tissue, comprising the steps of:

providing a source of pulsed ultrasound energy having a total power of between 5.8 and 17 watts, a pulse duration of approximately 0.5 seconds, an interval between pulses of approximately 5 seconds, and total pulse stream time of approximately 50 seconds; and

applying the provided pulsed ultrasound energy to the target tissue to create a thermal time-course by raising the target tissue temperature up to approximately eleven degrees Celsius during application of the ultrasound energy, while maintaining the long term temperature rise of the target tissue to only one degree Celsius or less over several minutes to stimulate cells of the target tissue to activate heat shock proteins without damaging the target tissue.

11. The method of claim 10, wherein a plurality of ultrasound beams are focused on the target tissue.

12. The method of claim 10, wherein the ultrasound energy applying step comprises the step of inserting a device into a cavity of a body and using the device to apply the pulsed ultrasound energy to the tissue.

13. The method of claim 12, wherein the device comprises an endoscope.

14. The method of claim 10, wherein the ultrasound energy applying step comprises the step of applying the pulsed ultrasound energy to an exterior area of a body which is adjacent to the target tissue or has a blood supply close to a surface of the exterior area of the body.

15. The method of claim 14, wherein the body area comprises an ear lobe and the pulsed ultrasound energy is applied to the blood flowing through the ear lobe to treat the blood.

16. The method of claim 10, wherein target tissue temperature is raised approximately ten degrees Celsius during the application of the ultrasound energy.

* * * * *